Half-year report · Q2
4539.TEDINET S100UPF3
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥15.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥30.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥14.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥76m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | −¥298m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥62m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥219m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥62m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥27m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥44m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥180m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥31m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥44m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥31m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥52.0bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥49.5bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥50.9bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥33.5bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥31.1bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥18.6bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥18.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.5bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.8bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.8bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥702m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥296m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥592m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥88m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥974m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-12.26 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-50.14 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.72 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.5% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥627m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥570m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥56m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥38m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥61m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥61m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.1bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.1bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥38m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥15.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥15.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥61m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥76m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥546m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥544m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥56m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥5m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥5m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥14.3bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.3bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥355m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥14.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥14.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥5m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | −¥298m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 534
| Item | Context | Value | Unit |
|---|---|---|---|
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所(スタンダード市場) | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)ジャパンソファルシム株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)東京都千代田区岩本町二丁目２番３号 | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)豊島薬品株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京都千代田区岩本町二丁目２番３号 | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)株式会社ＳＢＩ証券 | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)東京都港区六本木一丁目６番１号 | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)日本生命保険相互会社（常任代理人 日本マスタートラスト信託銀行株式会社） | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内一丁目６番６号（東京都港区赤坂一丁目８番１号） | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)今村 均 | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)千葉県東金市 | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)ゼリア新薬工業株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)東京都中央区日本橋小舟町10番11号 | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)日本ケミファ従業員持株会 | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)東京都千代田区岩本町二丁目２番３号 | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)山口 一城 | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)株式会社きらぼし銀行（常任代理人 株式会社日本カストディ銀行） | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)東京都港区南青山三丁目10番43号（東京都中央区晴海一丁目８番12号） | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)シオノケミカル株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)東京都中央区八重洲二丁目10番８号 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |